Here are three things to know.
1. The Dermapace System is an external shock wave device that uses pulses of energy to stimulate wound healing.
2. The device is intended to treat chronic, full-thickness diabetic foot ulcers no larger than 16 centimeters.
3. Recent clinical trials found diabetic patients treated with the Dermapace System exhibited an increase in wound healing 24 weeks after treatment and had a 44 percent wound closure rate, compared to just 30 percent for the control group.
More articles on supply chain:
FDA ends 2017 with 46 new drug approvals – the most in 2 decades
California city could be first in US to use drones to deliver blood
Mold-contaminated antibiotic recalled nationwide: 5 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.